Cyltezo

Cyltezo is a biologic medication used in the treatment of various autoimmune diseases. It is a biosimilar to adalimumab, which is marketed under the brand name Humira. Cyltezo is produced by Boehringer Ingelheim and was approved by the U.S. Food and Drug Administration (FDA) for use in the United States.

Medical Uses

Cyltezo is indicated for the treatment of several autoimmune conditions, including:

• Rheumatoid arthritis
• Psoriatic arthritis
• Ankylosing spondylitis
• Crohn's disease
• Ulcerative colitis
• Plaque psoriasis
• Juvenile idiopathic arthritis

Mechanism of Action

Cyltezo works by inhibiting tumor necrosis factor (TNF), a substance in the body that causes inflammation in autoimmune diseases. By blocking TNF, Cyltezo helps reduce the inflammatory response and alleviate symptoms associated with these conditions.

Administration

Cyltezo is administered via subcutaneous injection. The dosage and frequency of administration depend on the specific condition being treated and the patient's response to the medication.

Side Effects

Common side effects of Cyltezo include:

• Injection site reactions
• Upper respiratory infections
• Headache
• Rash

Serious side effects may include:

• Serious infections
• Malignancies
• Hepatitis B reactivation
• Heart failure

Approval and Regulation

Cyltezo was approved by the FDA in August 2017 as a biosimilar to Humira. It is subject to the same regulatory standards and monitoring as other biologic medications.

Related Pages

• Adalimumab
• Biosimilar
• Autoimmune disease
• Tumor necrosis factor
• Boehringer Ingelheim
• FDA